Why Is CV Sciences Stock Up Today?
CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results.
Biden’s Pardon For Cannabis Offenders: 27 Reactions From Politicians, Industry Executives And Advocacy Orgs
President Joe Biden announced on Thursday that he will pardon all prior federal offenses for simple marijuana possession, sending
The CBD Gold Rush Is Over (And That’s A Great Thing For Consumers)
By Bharat Ayyar
Disclaimer: I am not a financial advisor. Nothing contained in this post should be construed as investment advice.
CV Sciences (OTC: CVSI), the company behind +PlusCBD, had a meteoric rise in 2018.
EXCLUSIVE: Keep Calm And Carry CBD Softgels With THC, CV Sciences Launches Relaxation Products
Hemp CBD manufacturer CV Sciences, Inc. (OTCQB: CVSI) has launched +PlusCBD Reserve Collection softgels to support stress relief and relaxation. This new CBD collection will be available online starting August 15th at $54.99 per 60-count bottle.
CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
CV Sciences, Inc. (OTCQB: CVSI) added +PlusCBD Relief Softgels to its wellness line of CBD products.
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in Dry January.
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
CV Sciences, Inc. (OTCQB: CVSI) is launching +PlusCBD Pain Relief topicals.
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
The Best Daily Overview Of The Cannabis Space
CV Sciences Announces New Distribution Agreement with GNC. $CVSI
Massachusetts cannabis prices continue to fall
Kentucky GOP Sen. Damon Thayer: "Medical cannabis is a slippery slope for recreational marijuana.”
Cantor Fitzgerald Maintains Neutral on CV Sciences, Lowers Price Target to $0.17
Cantor Fitzgerald analyst Pablo Zuanic maintains CV Sciences (OTC:CVSI) with a Neutral and lowers the price target from $0.42 to $0.17.
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021.
Contents